Quick Facts
| Property | Value |
|---|---|
| Category | Growth Hormone Secretagogue |
| Risk Level | Moderate |
| Research Status | Limited Human Research / Moderate Preclinical Research |
| Administration | Subcutaneous Injection |
| Typical Frequency | 1–3 Times Daily |
| Estimated Half-Life | Short-Acting (Reported) |
| Primary Research Interest | Growth Hormone Release / Recovery Support / Endocrine Signaling |
This material is provided strictly for educational and informational purposes related to peptide research and growth hormone signaling compounds. Ipamorelin is a biologically active growth hormone secretagogue capable of altering growth hormone and metabolic signaling pathways. Information presented here should not be interpreted as medical advice, treatment recommendations, or encouragement of unsupervised use.
1. Summary
Ipamorelin is an experimental growth hormone secretagogue researched for its ability to stimulate pulsatile growth hormone release through selective ghrelin receptor activation. Unlike several older growth hormone releasing peptides (GHRPs), Ipamorelin has been investigated for producing comparatively selective growth hormone release with reduced effects on ACTH, cortisol, and prolactin signaling.
Research interest in Ipamorelin commonly centers around growth hormone optimization, recovery support, endocrine signaling, and its potential use alongside GHRH analogs such as CJC-1295.
What People Commonly Claim
- Improved sleep quality
- Enhanced recovery from training
- Increased growth hormone production
- Improved body composition
- Fat-loss support
- Fewer side effects than older GHRPs
- Excellent synergy with CJC-1295
What the Literature Actually Shows
- Ipamorelin stimulates growth hormone release through ghrelin receptor activation.
- Available evidence supports a comparatively selective growth hormone secretagogue profile.
- Published literature suggests less ACTH, cortisol, and prolactin stimulation than several older GHRPs.
- Evidence supporting sleep, recovery, and body-composition benefits remains considerably weaker than evidence supporting growth hormone release itself.
- Long-term human safety data remain limited.
CKF Transparency Note: Ipamorelin is widely discussed as one of the more selective growth hormone secretagogues because available literature suggests it stimulates growth hormone release while producing less ACTH, cortisol, and prolactin elevation than several older GHRP compounds. However, despite its popularity within peptide communities, the accessible evidence base remains relatively small, and many claims regarding sleep enhancement, body-composition improvement, and long-term recovery benefits exceed the strength of currently available human research. Most published evidence focuses on growth hormone release and mechanistic effects rather than long-term clinical outcomes.
2. Reconstitution Guide
- Vial Size: 10 mg
- Dilutant Type: BAC Water
- Amount of Dilutant Added: 2.5 mL
- Final Concentration: 4.00 mg/mL
At this concentration:
• 200 mcg = 0.050 mL (5.0 units)
• 600 mcg = 0.150 mL (15.0 units)
3. Route of Administration
Ipamorelin is most commonly administered as a subcutaneous injectable growth hormone secretagogue.
- Primary Route: SubQ Injection
- Preferred Timing: Commonly administered in fasted states
- Administration Notes: Frequently researched alongside GHRH analogs in an attempt to enhance pulsatile growth hormone release.
4. Typical Research Protocols
- Product Strength: 4.00 mg/mL
- Typical Delivered Amount: 200–600 mcg daily
- Frequency: Split between 1–3 doses daily
- Cycle Length: No standardized research protocol exists; duration recommendations vary substantially across experimental communities
- Special Notes: Ipamorelin is frequently paired with CJC-1295 or other GHRH analogs. Although workout recovery, sleep support, and body-composition benefits are commonly discussed, much of this guidance originates from anecdotal experience rather than controlled human research. Conservative dosing and long-term consistency are commonly emphasized.
5. Mechanism of Action
Ipamorelin functions by selectively stimulating ghrelin receptors involved in pulsatile growth hormone release pathways.
- Growth hormone release signaling
- Selective ghrelin receptor activation
- Potential IGF-1 pathway support
- Recovery-related signaling pathways
- Metabolic pathway modulation
- Comparatively limited ACTH, cortisol, and prolactin stimulation versus older GHRPs
Compared with compounds such as GHRP-2, GHRP-6, and Hexarelin, Ipamorelin is commonly regarded as one of the more selective growth hormone secretagogues currently available.
6. Potential Benefits
- Potential increase in growth hormone signaling
- Potential IGF-1 pathway support
- Enhanced recovery support
- Possible sleep-quality improvements
- Potential body-composition support
- Possible synergistic effects with GHRH analogs
7. Potential Risks / Side Effects
Moderate
- Water retention
- Fatigue
- Numbness or tingling
- Potential insulin sensitivity changes
- Headaches
- Injection-site irritation
- Potential endocrine disruption when combined with multiple hormone-modulating compounds
8. Half-Life
Ipamorelin is commonly described as a short-acting growth hormone secretagogue. Although human pharmacokinetic data remain limited, available evidence suggests a relatively brief duration of direct activity compared with longer-acting growth hormone–releasing compounds.
Because of this shorter duration, many experimental protocols utilize multiple daily administrations or pair Ipamorelin with longer-acting GHRH analogs in an attempt to support sustained pulsatile growth hormone signaling.
Despite its shorter activity profile, downstream growth hormone and IGF-1 signaling effects may persist considerably longer than measurable circulating peptide concentrations.
9. Storage Information
- Store refrigerated before and after reconstitution
- Protect from direct light exposure
- Avoid repeated freeze-thaw cycles
- Maintain sterile handling practices during preparation
10. Contraindications / Warnings
- Active cancer concerns
- Uncontrolled diabetes
- Pregnancy or breastfeeding
- Known hypersensitivity to peptide compounds
- Use alongside multiple hormone-modulating compounds without supervision
11. Further Study
Tier 1 — Direct Ipamorelin Research
Tier 2 — Growth Hormone Secretagogue Reviews
- The Safety and Efficacy of Growth Hormone Secretagogues
- Growth Hormone Secretagogues: History, Mechanism of Action, and Clinical Utility
- Beyond the Androgen Receptor: The Role of Growth Hormone Secretagogues in the Modern Management of Hypogonadal Men
- The Growth Hormone Secretagogue Ipamorelin Counteracts Glucocorticoid-Induced Decrease in Bone Formation of Adult Rats
Current Evidence Gaps
- Long-term human safety outcomes
- Long-term endocrine effects
- Sleep-quality outcomes in controlled human trials
- Body-composition outcomes in healthy individuals
- Optimal dosing and protocol standardization
- Comparative human trials versus GHRP-2, GHRP-6, and Hexarelin
12. Research References
- PubMed
- PubMed Central (PMC)
- NIH Publications
- Endocrinology literature
- Growth hormone secretagogue literature
- Peer-reviewed growth hormone and metabolism journals
13. Last Reviewed
June 2026